HPV Clinical Trial
Official title:
A Phase 1 Study to Evaluate the Immunologic Mechanisms Underlying Wart Resolution After Intralesional Immunotherapy With Candida Antigen
The purpose of this study is to look at how people respond to the treatment of warts through use of the Candida antigen to get an immune response to rid the body of human papillomavirus (HPV). The immune system is the part of the body that fights infections like HPV which causes warts. This research study will examine the response of your wart when injected with a portion of a common yeast (candida) which is the study drug. Your immune system response will also be looked at by doing a test called an ELISPOT assay. This test is done on blood samples. The results of this test may help us to determine how the Candida antigen affects your wart.
The use of recall antigens for treating warts is not yet Food and Drug Administration (FDA) approved. The primary goal of this work was to assess the safety of Candin as an investigational new drug (IND) for the treatment of warts. In addition, clinical resolution of treated and untreated warts was evaluated and immunologic responses were examined using an ex vivo interferon-γ enzyme-linked immunospot (IFN-γ ELISPOT) assay in order to elucidate the immunologic mechanisms behind the successful regression of warts in patients undergoing Candin injection immunotherapy. ;
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05736588 -
Elimisha HPV (Human Papillomavirus)
|
N/A | |
| Completed |
NCT01105000 -
Human Papilloma Virus (HPV) Knowledge and Attitudes and the Role of (SES) Socioeconomic Status and Ethnicity
|
||
| Recruiting |
NCT06147388 -
Regression of Cervical Precancerous Lesions and Associated Risk Factors
|
||
| Recruiting |
NCT04708470 -
A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06109870 -
Prevención en Sus Manos: Feasibility of a Novel Community-Based Strategy to Improve Access to Cervical Cancer Screening
|
N/A | |
| Completed |
NCT03082950 -
HPV Infections, Cancer of the Vulva and Therapeutical Success
|
||
| Recruiting |
NCT01512784 -
Long Term Immunogenicity of Quadrivalent Human Papillomavirus Vaccine (Gardasil®)in HIV-infected Adolescents and Young Adults
|
Phase 3 | |
| Recruiting |
NCT05363709 -
BALSTILIMAB on Viral Clearance in HPV+ Oropharyngeal Cancer Patients
|
Phase 2 | |
| Completed |
NCT01231945 -
Low-Cost Molecular Cervical Cancer Screening Study
|
N/A | |
| Recruiting |
NCT01011712 -
The Natural History of Severe Viral Infections and Characterization of Immune Defects in Patients Without Known Immunocompromise
|
||
| Recruiting |
NCT05996016 -
Gut and Vaginal Microbiota Profile Study for HIV Women
|
||
| Completed |
NCT05907187 -
Research in Ethno-Medicine and Education (REMED)
|
N/A | |
| Completed |
NCT05616767 -
Prevention and Screening for Early Detection of HPV-related Cancers in Gay and Bisexual Men in Tanzania
|
N/A | |
| Completed |
NCT02247999 -
Improving Cervical Cancer Screening Among HIV-Infected Women in India
|
||
| Terminated |
NCT01468636 -
A RTC to Examine the Effectiveness of 400 mg of Oral Zinc Gluconate as Adjunctive Therapy for Ano-genital Warts
|
Phase 4 | |
| Active, not recruiting |
NCT04965792 -
Post-treatment Surveillance in HPV+ Oropharyngeal SCC
|
||
| Active, not recruiting |
NCT05006833 -
Text and Talk: A Multi-level Intervention to Increase Provider HPV Vaccine Recommendation Effectiveness
|
N/A | |
| Enrolling by invitation |
NCT06120205 -
SELF-CERV Pivotal Study: SELF-Collection for CERVical Cancer Screening
|
N/A | |
| Recruiting |
NCT05208710 -
PANHPVAX, Study of a New HPV Vaccine in Healthy Volunteers
|
Early Phase 1 | |
| Completed |
NCT05462249 -
Impact of Catch-up HPV Vaccination
|